Test Price
2,800 AED✅ Home Collection Available
PLEKHG4 Genetic SCA4 Test in UAE | 2,800 AED | DHA Licensed NGS Analysis
Executive Summary & Core Metrics
This is the UAE’s definitive Next‑Generation Sequencing (NGS) test for PLEKHG4‑associated Spinocerebellar Ataxia Type 4 (SCA4). We deliver 99.9% diagnostic sensitivity through our ISO‑accredited DHA‑licensed facility, supported by hospital‑grade home collection, cold‑chain transport, and post‑test clinical guidance. Direct insurance billing verification via WhatsApp +971 54 548 8731.
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- ✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (8 AM‑11 PM).
- ✓ Clinical Guidance: Telephonic Post‑Test Clinical Guidance in result interpretation.
- ✓ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This state‑of‑the‑art NGS test sequences the entire PLEKHG4 gene to detect pathogenic variants responsible for autosomal dominant Spinocerebellar Ataxia Type 4 (SCA4). It provides definitive molecular confirmation for patients with progressive ataxia, dysarthria, and sensory neuropathy. As the only UAE‑based DHA‑governed NGS service for SCA4, we ensure results are clinically actionable within 3–4 weeks.
| Feature | Our PLEKHG4 NGS Test | Closest Alternative (Standard Ataxia Panel) |
|---|---|---|
| Precision | Gene‑specific, full‑coverage NGS with >99.9% analytical sensitivity | Multi‑gene panel may miss rare PLEKHG4 variants or offer lower depth |
| Methodology | Next‑Generation Sequencing (NGS) aligned to validated clinical datasets | Often Sanger sequencing‑based, slower and less comprehensive |
| Turnaround | 3–4 weeks | 4–6 weeks typical |
| Reporting | Comprehensive clinical report with ICD‑10 & LOINC annotation | Basic variant list without genetic counseling context |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics specialist, I emphasize that a genetic test is a powerful component of a broader diagnostic framework. The PLEKHG4 result must be integrated with neurological examination, family pedigree analysis, and imaging data before any therapeutic or management decisions are made.” — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403.
Clinical Advisory Notice
Safety Exclusion & Red Flags
- Exclusion Criteria: This test is not intended for asymptomatic minors without a court‑appointed guardian’s consent. Do not proceed if you have not received pre‑test genetic counselling.
- Emergency Red Flags: If you suddenly develop severe balance loss, double vision, difficulty swallowing, or breathing problems, seek immediate emergency care—do not wait for genetic results.
- Preparation: No fasting required. For blood draw, ensure you are well‑hydrated. Inform the phlebotomist of any anticoagulant medications you are taking.
Patient FAQ & Clinical Guidance
1. What exactly does this PLEKHG4 test detect and how does it help diagnose SCA4?
This NGS test identifies pathogenic mutations in the PLEKHG4 gene, confirming a molecular diagnosis of Spinocerebellar Ataxia Type 4 (SCA4) with over 99.9% accuracy. The result provides definitive genetic evidence to support or refine a clinical diagnosis of progressive ataxia.
2. Can I use this test for predictive health screening if I have a family history of ataxia?
Yes, after mandatory genetic counseling, asymptomatic adults with a known PLEKHG4 family variant can undergo predictive testing aligned to UAE PDPL and DHA consent protocols. A three‑generation pedigree analysis is required prior to testing.
3. How will I receive my results and will a doctor explain them?
A secure, encrypted report with full variant interpretation is delivered within 3–4 weeks, complemented by a complimentary telephonic clinical guidance session with a DHA‑licensed genetics specialist who will walk you through the implications and next steps.
UAE Regulatory & Data Privacy Adherence
This testing service operates under the governance of the Dubai Health Authority (DHA) and adheres to the following UAE federal frameworks:
- Data Protection: Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensuring all genetic data is encrypted, anonymized, and processed with explicit patient consent.
- Health Information Governance: Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governing the secure electronic transmission and storage of laboratory records.
- Medical Liability & Patient Safety: Federal Decree‑Law No. 4 of 2016 on Medical Liability – safeguarding clinical standards and patient rights throughout the diagnostic pathway.
ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139) | DHA Facility License: 1143 | All testing follows UAE federal data protection and health information governance regulations.
Clinical & Logistical Metadata
| Test Name | PLEKHG4 Genetic SCA4 Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (Peripheral), Extracted DNA, or One Drop Blood on FTA Card |
| Methodology Used | Next‑Generation Sequencing (NGS) |
| ICD-10-CM Code | G11.8 |
| LOINC Code | 21684-4 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians